THANK YOU FOR SUBSCRIBING
Scientists at Epirium have discovered a previously unknown hormonal pathway that seems to be an endogenous modulator of mitochondria biogenesis - the formation of new mitochondria. One of the distinctive properties of this hormonal pathway is the generation of new, functional mitochondria, coupled with restoring the structure and function of previously atrophic tissue, particularly that of neuromuscular and central nervous systems
Fremont, CA: Epirium Bio Inc., formerly known as Cardero Therapeutics Inc., raised USD 85 million in a Series A funding round participated by Longitude Capital, ARCH Venture Partners, Bluebird Ventures, Adams Street Partners, Vertex Ventures HC, and The Longevity Fund. The San Francisco-based startup is a clinical-stage biopharmaceutical company that develops therapeutics that optimize both tissue bioenergetics and structure through a novel mechanism of action discovered by the company. The proceeds from the new funding round will be used towards the development of the company's innovative scientific platform. The company aims to advance its first clinical candidate next year, initially in Becker Muscular Dystrophy, followed by drug development targeting other progressive neuromuscular disorders associated with mitochondrial depletion.
"Epirium has discovered a novel class of therapeutics addressing not only the loss of muscle structure but also the underlying mitochondrial dysfunction, which represents another major progression factor in diseases of muscle failure," stated Professor Craig McDonald of the University of California at Davis and principal investigator of Epirium’s first company-sponsored study. “I am pleased to be working with Epirium to advance the new concept of therapeutic mitochondrial biogenesis as a potential treatment for patients suffering from muscular dystrophy.”
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Scientists at Epirium have discovered a previously unknown hormonal pathway that seems to be an endogenous modulator of mitochondria biogenesis - the formation of new mitochondria. One of the distinctive properties of this hormonal pathway is the generation of new, functional mitochondria, coupled with restoring the structure and function of previously atrophic tissue, particularly that of neuromuscular and central nervous systems. This coupling of pathways mimics a physiological process that is seen in response to physical response to physical exercise, which is essential for the proper functioning of organs.
With these insights, Epirium has embarked on a new journey to pursue a novel and differentiated pharmacological approach for the treatment of diseases characterized by mitochondrial depletion or dysfunction leading to subsequent organ failure. "We are thrilled to partner with an exceptional team of visionary and highly respected investors, who have a strong track record in uncovering and backing only the most promising science," said Russell Cox, President, and CEO of Epirium. "I look forward to leading a very experienced management team as we advance the application of the unique biology we have discovered, which has already produced promising signals of clinical benefit."
"We are impressed with the executive team's extensive experience and passion for developing and bringing to market life-saving therapies," said Paul Berns, Chairman of the Board and Venture Partner at ARCH Venture Partners. "We look forward to partnering with our distinguished syndicate to propel Epirium's scientific platform and lead candidates forward for the benefit of patients."
See Also :- Top Healthcare Solution Companies

More in News